Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics

Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics

Currently, there is a multitude of CD3 bispecifics with different molecular designs and binding properties in preclinical and clinical development for the treatment of liquid or solid tumors. The key safety concerns with CD3 bispecifics are excessive release of cytokines, which may translate to pote...

Full description

Bibliographic Details
Main Authors: Cris Kamperschroer, Jacintha Shenton, Hervé Lebrec, John K. Leighton, Paul A. Moore, Oliver Thomas
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Journal of Immunotoxicology
Subjects:
cd3 bispecific
redirected t-cell therapy
nonclinical safety
toxicity
cynomolgus monkey
clinical safety management
cytokine release
clinical starting dose
first-in-human dose
fda
Online Access:http://dx.doi.org/10.1080/1547691X.2020.1729902

Internet

http://dx.doi.org/10.1080/1547691X.2020.1729902

Similar Items